Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|July 2, 2016
- Pharmaceutical Technology-07-02-2016
- Volume 40
- Issue 7
Single-Use Bioreactor Reduces Turnaround Time
The BIOne single-use bioreactor from Distek is a benchtop scale single-use bioreactor (SUB) system for mammalian cell growth and recombinant protein production.
The BIOne single-use bioreactor from Distek is a benchtop scale single-use bioreactor (SUB) system for mammalian cell growth and recombinant protein production. The pre-sterilized BIOne system is engineered with a disposable headplate welded to a tri-layer liner that can be easily inserted into a non-sterile bioreactor glass vessel, converting it to a sterile, disposable SUB. All materials are USP Class VI, animal derivative free, and used in existing single-use products. The system reduces turnaround time by allowing users to transition to a disposable platform while using existing equipment, without compromising the scalability of current processes.
Articles in this issue
over 10 years ago
FDA and Manufacturers Intensify Concerns about Data Integrityover 10 years ago
Planning a Biologics Facility Start Upover 10 years ago
Solid-Dosage Packaging Trendsover 10 years ago
Quality System for a Regulatory Affairs Departmentover 10 years ago
Data Integrity Challenges in Manufacturingover 10 years ago
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017over 10 years ago
Cleaning Bioreactors and Fermenters with CIP Systemsover 10 years ago
Maximize Efficiency in Tooling Maintenanceover 10 years ago
Recognizing Pharma Industry Excellenceover 10 years ago
Expanding the Chiral ToolboxRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.